Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-zeta EBV-CTLs for High-risk ALL Post-HSCT
NCT01195480Phase 2Terminated
- Sponsor
- University College London
- Start
- May 2012
- Primary completion
- Nov 2015
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of CD19-zeta transduced Epstein-Barr virus-specific cytotoxic T lymphocytes in acute lymphoblastic leukemia (ALL), sponsored by University College London. Started May 2012; status: terminated.
02
Drugs
CD19-zeta transduced Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01195480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195480.